



Symbio Pharmaceuticals Limited
San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

June 20, 2008

Symbio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director, President and Chief Executive Officer

Symbio Completes Patient Enrollment for Mantle Cell Lymphoma in Bendamustine Phase II Clinical Study

TOKYO, June 20, 2008 - Symbio Pharmaceuticals Limited has completed target enrollment of patients with mantle cell lymphoma for an ongoing Phase II clinical study of bendamustine after completing enrollment of patients with indolent non-Hodgkin's lymphoma (I-NHL). The Japan study is being conducted at 18 institutions nationwide since its initiation in December, 2007. The company intends to collect efficacy and safety data in preparation for NDA filing. Due to completion of enrollment for I-NHL and mantle cell lymphoma (MCL) patients earlier than originally planned, the company has expedited its development timeline of bendamustine, with submission of the NDA now expected in the 4th quarter of 2009.

Symbio has acquired exclusive rights for the development and commercialization of bendamustine hydrochloride in Japan, China (Hong Kong), Taiwan, Korea and Singapore from Astellas Pharma GmbH (currently, Astellas Deutschland GmbH, München, Germany). In Germany, bendamustine hydrochloride is used as an anticancer drug under the brand name "Ribomustin[®]". On March 20, 2008, Cephalon, Inc. (Frazer, PA) received NDA approval from US FDA for TREANDA[®] (bendamustine hydrochloride) in the treatment of patients with chronic lymphocytic leukemia (CLL). Cephalon has filed a supplemental NDA with FDA for use in patients with indolent low-grade NHL who have progressed during or following treatment with rituximab or a rituximab-containing regimen, and expects to receive FDA approval by the 4th quarter of this year. MAAs have also been filed with EMEA for use of bendamustine hydrochloride in the treatment of I-NHL, CLL and multiple myeloma (MM) in 13 European countries, excluding Germany.

[Company Profile]

SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan, with the corporate mission of addressing underserved therapeutic areas having high medical need in Japan, Korea, Taiwan and other Asia Pacific Rim countries. SymBio's main focus lies in the development of drugs within three therapeutic areas: oncology, hematology and autoimmune disease. Through its proprietary in-house search and evaluation process and experienced management team with strong development expertise in biopharmaceuticals, SymBio is able to implement unique strategies in the development of drug candidates, thereby bringing much-needed therapies to market in an expeditious manner.

For further information, please contact:

SymBio Pharmaceuticals Limited.

Osamu Ogawa,

Board Director, Senior Corporate Officer,

Senior Director, Research & Development

Tel: +081(0)3 5472 1127

E-mail: Please send your inquiry through "INQUIRY" in our homepage

URL:<http://www.symbiosis.co.jp>